AR090884A1 - Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc - Google Patents
Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gccInfo
- Publication number
- AR090884A1 AR090884A1 ARP130101458A ARP130101458A AR090884A1 AR 090884 A1 AR090884 A1 AR 090884A1 AR P130101458 A ARP130101458 A AR P130101458A AR P130101458 A ARP130101458 A AR P130101458A AR 090884 A1 AR090884 A1 AR 090884A1
- Authority
- AR
- Argentina
- Prior art keywords
- gcc
- same
- antibody molecules
- directed therapy
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G01N33/5759—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639376P | 2012-04-27 | 2012-04-27 | |
| PCT/US2013/038542 WO2013163633A1 (en) | 2012-04-27 | 2013-04-27 | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090884A1 true AR090884A1 (es) | 2014-12-10 |
Family
ID=49477498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101458A AR090884A1 (es) | 2012-04-27 | 2013-04-29 | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc |
Country Status (41)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102573908B (zh) | 2009-10-23 | 2014-12-17 | 米伦纽姆医药公司 | 抗gcc抗体分子及其相关组合物和方法 |
| AU2014339719B2 (en) * | 2013-10-21 | 2020-05-07 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
| EP3104849B1 (en) | 2014-02-14 | 2019-08-28 | BioVentures, LLC | Acetaminophen protein adducts and methods of use thereof |
| US10570216B2 (en) | 2014-12-03 | 2020-02-25 | Bioventures, Llc | Anti-acetaminophen antibodies and acetaminophen protein adducts |
| EP3356418A4 (en) | 2015-10-01 | 2019-07-03 | The Centre for Drug Research and Development | ANTI-PODOCALYXIN ANTIBODIES AND METHODS OF USE THEREOF |
| JP7356351B2 (ja) * | 2016-12-12 | 2023-10-04 | エクセラ・バイオサイエンシーズ・インコーポレイテッド | マイクロキャピラリーアレイを使用したスクリーニングのための方法およびシステム |
| KR102080887B1 (ko) * | 2017-11-07 | 2020-02-24 | 고려대학교 산학협력단 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
| US11568657B2 (en) | 2017-12-06 | 2023-01-31 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
| EP3721372A1 (en) * | 2017-12-06 | 2020-10-14 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
| US20210330736A1 (en) * | 2018-09-05 | 2021-10-28 | Universiteit Van Amsterdam | Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease |
| WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
| AU2021282629A1 (en) * | 2020-06-02 | 2022-12-01 | Teijin Pharma Limited | Anti-IGF-1 receptor humanized antibody |
| CN116917329A (zh) * | 2020-12-17 | 2023-10-20 | 合肥梧桐生物科技有限公司 | Gucy2c结合分子及其用途 |
| WO2022216079A1 (ko) * | 2021-04-07 | 2022-10-13 | 주식회사 엘지화학 | Gucy2c 결합 폴리펩타이드 및 그의 용도 |
| EP4594364A1 (en) * | 2022-09-28 | 2025-08-06 | Legend Biotech Ireland Limited | Antibody and chimeric antigen receptors targeting gcc and methods of use thereof |
| KR20250099224A (ko) | 2022-11-01 | 2025-07-01 | 하이델베르크 파마 리서치 게엠베하 | 항-gucy2c 항체 및 이의 용도 |
| CN116535514B (zh) * | 2023-06-15 | 2024-02-02 | 上海斯丹赛生物技术有限公司 | 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用 |
| CN117069848B (zh) * | 2023-08-02 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人cd146兔单克隆抗体及其应用 |
| WO2025061149A1 (zh) * | 2023-09-21 | 2025-03-27 | 南京传奇生物科技有限公司 | 抗gcc抗体、嵌合抗原受体及其用途 |
| EP4566631A1 (en) | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
| CN120965861A (zh) * | 2025-10-22 | 2025-11-18 | 杭州博茵生物技术有限公司 | 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
| US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
| US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| JP4194113B2 (ja) | 1993-10-26 | 2008-12-10 | トーマス・ジェファーソン・ユニバーシティ | 結腸直腸癌細胞に特異的に結合する組成物およびその使用方法 |
| US7097839B1 (en) | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
| US6455251B1 (en) | 1994-09-13 | 2002-09-24 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| WO1997042506A1 (en) | 1996-05-03 | 1997-11-13 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| CA2254082C (en) | 1996-05-03 | 2012-09-11 | Thomas Jefferson University | Metastatic colorectal cancer vaccine |
| US6120995A (en) | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| US8092514B1 (en) | 1998-11-16 | 2012-01-10 | Boston Scientific Scimed, Inc. | Stretchable anti-buckling coiled-sheet stent |
| US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| ATE469242T1 (de) | 2000-03-27 | 2010-06-15 | Univ Jefferson | Zusammensetzungen und methoden zur identifizierung und zum targeting von krebszellen aus dem verdauungskanal |
| TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| ES2372686T3 (es) | 2001-01-26 | 2012-01-25 | Inhibitex, Inc. | Anitcuerpos monoclonales dirigidos contra la proteína clfa y modo de empleo en el tratamiento y prevención de infecciones. |
| EP1379224B2 (en) | 2001-03-29 | 2013-10-02 | Synergy Pharmaceuticals, Inc. | Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis |
| NZ529494A (en) | 2001-04-13 | 2005-08-26 | Biogen Idec Inc | Antibodies to VLA-1 |
| ES2289174T3 (es) | 2001-12-28 | 2008-02-01 | Amgen Fremont Inc. | Anticuerpos contra el antigeno muc-18. |
| US20040110933A1 (en) | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004071436A2 (en) | 2003-02-10 | 2004-08-26 | Thomas Jefferson University | The use of gcc ligands |
| JP4889493B2 (ja) | 2003-05-14 | 2012-03-07 | ドマンティス リミテッド | ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法 |
| US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
| EP1781339B1 (en) | 2004-06-25 | 2013-12-25 | Thomas Jefferson University | Guanylyl cyclase C ligands |
| CN105085678B (zh) | 2004-12-21 | 2019-05-07 | 阿斯利康公司 | 血管生成素-2的抗体及其应用 |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| AU2008261102B2 (en) | 2007-06-04 | 2013-11-28 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8207295B2 (en) | 2008-06-04 | 2012-06-26 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| BRPI0815370B8 (pt) | 2007-08-10 | 2021-05-25 | Regeneron Pharma | anticorpos humanos de alta afinidade contra o fator de crescimento neural humano e seu uso, molécula de ácido nucleico, vetor de expressão, método para produção de um anticorpo anti-ngf humano e composiçao farmacêutica |
| CN101889021B (zh) * | 2007-08-10 | 2016-06-08 | 詹森生物科技公司 | 作为疾病指标的免疫球蛋白裂解片段与用于检测和结合所述片段的组合物 |
| ATE522809T1 (de) * | 2007-11-30 | 2011-09-15 | Genentech Inc | Vegf-polymorphismen und antiangiogenese-therapie |
| CA2760050A1 (en) | 2008-05-13 | 2009-11-19 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
| EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| CA2745288A1 (en) * | 2008-12-03 | 2010-06-10 | Alisa Kabcenell | Antibodies for guanylyl cyclase receptors |
| AU2010213578B2 (en) * | 2009-02-12 | 2015-01-29 | Cell Signaling Technology, Inc. | Mutant ROS expression in human cancer |
| EP2401394B1 (en) | 2009-02-25 | 2013-11-27 | Diagnocure Inc. | Method for detecting metastasis of gi cancer |
| US8598188B2 (en) * | 2009-03-12 | 2013-12-03 | Kinki University | Method for predicting therapeutic efficacy of chemotherapy on non-small-cell lung cancer |
| US20120225099A1 (en) | 2009-06-15 | 2012-09-06 | Thomas Jefferson University | Compositions for and methods of activating guanylyl cyclase c |
| EP2491116A4 (en) | 2009-10-22 | 2013-12-11 | Univ Jefferson | CELL-BASED ANTI-CANCER COMPOSITIONS AND METHODS OF MAKING AND USING SAME |
| CN102573908B (zh) * | 2009-10-23 | 2014-12-17 | 米伦纽姆医药公司 | 抗gcc抗体分子及其相关组合物和方法 |
| JP2013534515A (ja) * | 2010-06-01 | 2013-09-05 | モナシュ ユニバーシティ | プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体 |
| EP2603239A2 (en) * | 2010-08-13 | 2013-06-19 | F.Hoffmann-La Roche Ag | Neuropilin as a biomarker for bevacizumab combination therapies |
| WO2013016662A1 (en) | 2011-07-28 | 2013-01-31 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
| US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
| KR20150122730A (ko) * | 2013-02-28 | 2015-11-02 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 암의 치료에서 항-gcc 항체-약물 콘주게이트 및 dna 손상 제제의 투여 |
-
2013
- 2013-04-27 LT LTEP13782061.9T patent/LT2841575T/lt unknown
- 2013-04-27 CA CA2871614A patent/CA2871614C/en active Active
- 2013-04-27 SG SG11201406855TA patent/SG11201406855TA/en unknown
- 2013-04-27 ME MEP-2019-257A patent/ME03560B/me unknown
- 2013-04-27 PE PE2014001908A patent/PE20142322A1/es active IP Right Grant
- 2013-04-27 ES ES13782061T patent/ES2749181T3/es active Active
- 2013-04-27 MX MX2014013081A patent/MX362020B/es active IP Right Grant
- 2013-04-27 RS RSP20191239 patent/RS59370B1/sr unknown
- 2013-04-27 EP EP13782061.9A patent/EP2841575B1/en active Active
- 2013-04-27 DK DK13782061.9T patent/DK2841575T3/da active
- 2013-04-27 GE GEAP201313644A patent/GEP201706737B/en unknown
- 2013-04-27 EA EA201491977A patent/EA034689B1/ru unknown
- 2013-04-27 WO PCT/US2013/038542 patent/WO2013163633A1/en not_active Ceased
- 2013-04-27 HR HRP20191690TT patent/HRP20191690T1/hr unknown
- 2013-04-27 JP JP2015509208A patent/JP6472746B2/ja active Active
- 2013-04-27 HU HUE13782061A patent/HUE046404T2/hu unknown
- 2013-04-27 SI SI201331582T patent/SI2841575T1/sl unknown
- 2013-04-27 CN CN201380033309.4A patent/CN104395470B/zh active Active
- 2013-04-27 SM SM20190536T patent/SMT201900536T1/it unknown
- 2013-04-27 MA MA37569A patent/MA37569B1/fr unknown
- 2013-04-27 NZ NZ701601A patent/NZ701601A/en not_active IP Right Cessation
- 2013-04-27 SA SA113340502A patent/SA113340502B1/ar unknown
- 2013-04-27 PL PL13782061T patent/PL2841575T3/pl unknown
- 2013-04-27 US US13/872,080 patent/US9000129B2/en active Active
- 2013-04-27 MY MYPI2014703176A patent/MY188442A/en unknown
- 2013-04-27 KR KR1020147032890A patent/KR102046435B1/ko not_active Expired - Fee Related
- 2013-04-27 PT PT137820619T patent/PT2841575T/pt unknown
- 2013-04-27 AU AU2013251312A patent/AU2013251312B2/en not_active Ceased
- 2013-04-27 UA UAA201412715A patent/UA117910C2/uk unknown
- 2013-04-29 TW TW102115363A patent/TWI631137B/zh active
- 2013-04-29 AR ARP130101458A patent/AR090884A1/es active IP Right Grant
-
2014
- 2014-10-23 ZA ZA2014/07723A patent/ZA201407723B/en unknown
- 2014-10-23 IL IL235307A patent/IL235307B/en active IP Right Grant
- 2014-10-24 PH PH12014502399A patent/PH12014502399B1/en unknown
- 2014-10-24 TN TN2014000454A patent/TN2014000454A1/fr unknown
- 2014-10-24 DO DO2014000242A patent/DOP2014000242A/es unknown
- 2014-10-27 CR CR20140497A patent/CR20140497A/es unknown
- 2014-10-27 CL CL2014002911A patent/CL2014002911A1/es unknown
- 2014-11-25 EC ECIEPI201428523A patent/ECSP14028523A/es unknown
- 2014-11-26 CO CO14260074A patent/CO7280144A2/es unknown
-
2015
- 2015-02-27 US US14/634,438 patent/US9273146B1/en active Active
-
2016
- 2016-01-19 US US15/000,950 patent/US20160130344A1/en not_active Abandoned
-
2017
- 2017-04-26 JP JP2017087084A patent/JP6517267B2/ja active Active
-
2019
- 2019-09-24 CY CY20191101005T patent/CY1122557T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090884A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
| PH12021550083A1 (en) | Human anti-tau antibodies | |
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| CY1122907T1 (el) | Διαγνωστικες αναλυσεις και kit για ανιχνευση υποδοχεα φολικου 1 | |
| CY1123515T1 (el) | Μεθοδοι αγωγης μιας ταυπαθειας | |
| MX366965B (es) | Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina. | |
| AR091649A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos | |
| AR088514A1 (es) | Inmunoligantes biespecificos dirigidos contra tnf | |
| AR088512A1 (es) | Anticuerpos dirigidos contra el tnf | |
| CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
| BR112015012933A2 (pt) | proteínas de ligação ao antígeno bcma | |
| UY32971A (es) | Proteínas de unión al antígeno de la il-23 humana | |
| BR112013021134A8 (pt) | Anticorpo isolado que se liga especificamente a ptk7 humano, seu uso, composição farmacêutica que o compreende, e ácido nucleico | |
| AR090923A1 (es) | Anticuerpos anti-il-23 | |
| AR090903A1 (es) | Anticuerpos e inmunoconjugados anti-pmel17 | |
| CO7151488A2 (es) | Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos | |
| AR063840A1 (es) | Anticuerpos humanos monoclonales para btla y metodos de uso | |
| EA201400579A1 (ru) | Антитела к il-36r | |
| MX345092B (es) | Anticuerpos anti-tau humanos,. | |
| BR112014003999A2 (pt) | anticorpo isolado que se liga a um epítopo próximo da membrana de mcsp humano, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo, método de tratamento de indivíduos portadores de câncer, método de undução da lise celular em indivíduos e teste imuno-histoquímico de mcsp | |
| DOP2013000218A (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
| BR112014032916A2 (pt) | anticorpos anti-fármacos e usos destes para o monitoramento de fármaco | |
| UY33274A (es) | Proteínas de unión a basigina | |
| BR112012028010A2 (pt) | anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero | |
| HK1219962A1 (zh) | 人抗白细胞介素-32抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |